Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (يفتح نافذة جديدة)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Source‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

مفهرسة‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (يفتح نافذة جديدة)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (يفتح نافذة جديدة)

Banan M.

Source‎: Ann Hematol 2013;92(3):289-99.

مفهرسة‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (يفتح نافذة جديدة)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (يفتح نافذة جديدة)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Source‎: Transfusion 2007;47(10):1830-6.

مفهرسة‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (يفتح نافذة جديدة)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (يفتح نافذة جديدة)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Source‎: Blood 1996;87(3):887-92.

مفهرسة‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (يفتح نافذة جديدة)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (يفتح نافذة جديدة)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Source‎: Iran J Blood Cancer 2009;1(4):147-50.

مفهرسة‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (يفتح نافذة جديدة)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (يفتح نافذة جديدة)

Karimi M, Cohan N, Pishdad P.

Source‎: Hematology 2015;20(1):53-7.

مفهرسة‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (يفتح نافذة جديدة)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (يفتح نافذة جديدة)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Source‎: Int J Hematol 2012;95(1):51-6.

مفهرسة‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (يفتح نافذة جديدة)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (يفتح نافذة جديدة)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Source‎: Hemoglobin 2014;38(2):115-8.

مفهرسة‎: PubMed 24471558

DOI‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (يفتح نافذة جديدة)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (يفتح نافذة جديدة)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Source‎: Blood 2013;121(12):2199-212.

مفهرسة‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (يفتح نافذة جديدة)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (يفتح نافذة جديدة)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Source‎: Sci Rep. 2022;12(1):2752.

مفهرسة‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (يفتح نافذة جديدة)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (يفتح نافذة جديدة)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Source‎: Haematologica 2004;89(10):1172-8.

مفهرسة‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (يفتح نافذة جديدة)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (يفتح نافذة جديدة)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Source‎: Arch Iran Med 2009;12(3):295-7.

مفهرسة‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (يفتح نافذة جديدة)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (يفتح نافذة جديدة)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Source‎: Eur J Haematol 1996;56(5):326-8.

مفهرسة‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (يفتح نافذة جديدة)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (يفتح نافذة جديدة)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Source‎: J Matern Fetal Med 1999;8(1):1-7.

مفهرسة‎: PubMed 10052837

DOI‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (يفتح نافذة جديدة)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (يفتح نافذة جديدة)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Source‎: Acta Haematol 2004;111(4):189-95.

مفهرسة‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (يفتح نافذة جديدة)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (يفتح نافذة جديدة)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Source‎: Ann Hematol 2001;80(8):492-5.

مفهرسة‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (يفتح نافذة جديدة)

Fetal globin induction--can it cure beta thalassemia? (يفتح نافذة جديدة)

Perrine SP.

Source‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

مفهرسة‎: PubMed 16304357

DOI‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (يفتح نافذة جديدة)